Benzothiazole PI3 kinase modulators for cancer treatment

US7928140B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Shon Booker · Thousand Oaks, US
• Noel D'Angelo · Thousand Oaks, US
• Derin D'Amico · Newbury Park, US
• Tae-Seong Kim · Yongin-si, KR
• Longbin Liu · Thousand Oaks, US
• Kristin Meagher · Thousand Oaks, US
• Mark H. Norman · Thousand Oaks, US
• Kathleen Panter · Cambridge, US
• Laurie B. Schenkel · Somerville, US
• Adrian L. Smith · Simi Valley, US
• Nuria A. Tamayo · Newbury Park, US
• Douglas A. Whittington · Waltham, US
• Ning Xi · Newbury Park, US
• Kevin Yang · San Gabriel, US

Key dates

• Filing date: Aug 1, 2008
• Grant date: Apr 19, 2011
• Expiry date: Aug 20, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula Iwherein each of A1, A2, A3, A4, X, R1 and R2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.